irblog.prnewswire.com

Altesa BioSciences' Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for ...

COLLEGE PARK, Ga., March 19, 2026 /PRNewswire/ -- Altesa BioSciences will present novel data regarding the mechanisms of action and anti-viral coverage of vapendavir and its newly discovered active ...
Yahoo Finance

Altesa, run by former Trump official, raises $75M for well-traveled lung drug

Atlanta biotechnology company Altesa BioSciences announced Thursday it closed a $75 million Series B round to advance a drug it sees as helpful treating multiple chronic lung conditions. Altesa's drug ...
irblog.prnewswire.com

Altesa BioSciences Appoints Brett Haumann, MBBCh, MBA, to its Board of Directors and Gwen Skloot, MD, ATSF, as Senior Vice President for Clinical Development

Dr. Haumann brings decades of respiratory drug development expertise in advancing novel therapies for complex pulmonary diseases; Dr. Skloot further strengthens Altesa's clinical leadership in COPD, ...
Pulse 2.0

Altesa BioSciences: $75 Million Series B Raised For Advancing Vapendavir For Chronic Lung Diseases

Altesa BioSciences, a clinical-stage pharmaceutical company focused on improving outcomes for people with chronic lung diseases, has closed an oversubscribed $75 million Series B financing round to ...
Yahoo Finance

New Altesa BioSciences Data: Vapendavir Demonstrates Anti-Viral Activity Against All Three Rhinovirus Species

PRAGUE, May 12, 2026 /PRNewswire/ -- Altesa BioSciences presented new research at the 2026 International Conference on Antiviral Research (ICAR) demonstrating that vapendavir, a rhinovirus capsid ...
Medindia

Altesa BioSciences Presents Positive Phase 2 Challenge Study Results for Vapendavir at American Thoracic Society International Conference 2026

Randomized, placebo-controlled challenge study demonstrated reduced viral load, reduced inflammation, maintained lung function and improved patient-reported outcomes in COPD patients treated with ...
Medindia

Altesa BioSciences Details Positive Topline Vapendavir Results from Phase 2 Placebo-Controlled Rhinovirus Challenge Study in COPD Patients

COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD ...
Morningstar%2c Inc.

Altesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officer

ATLANTA, July 21, 2026 /PRNewswire/ -- Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, ...
Wall Street Journal

Altesa Bio Hires Former GSK Official for Antiviral Drug Development

Altesa BioSciences has hired a top pharmaceutical executive to help develop a drug for a respiratory infection that is particularly serious for people with chronic obstructive pulmonary disease. Dr.
Morningstar%2c Inc.

Altesa BioSciences Appoints Brett Haumann, MBBCh, MBA, to its Board of Directors and Gwen Skloot, MD, ATSF, as Senior Vice President for Clinical Development

Altesa BioSciences is a clinical-stage pharmaceutical company, led by global experts in respiratory medicine and infectious diseases. We are dedicated to improving the lives of people with chronic ...
streetinsider

Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conference

WASHINGTON, June 5, 2026 /PRNewswire/ -- Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, ...